Sterling Pharma Solutions has completed a multi-million-pound expansion of its dedicated bioconjugation facility in Deeside, Wales, doubling manufacturing capacity and increasing batch scale to 500 litres. The expansion includes a new Good Manufacturing Practice (GMP) manufacturing suite with a 500-litre reactor and a 1,400-square-foot Grade C cleanroom. The facility can handle highly potent compounds with […]
The post Sterling doubles ADC manufacturing capacity at Welsh facility appeared first on Pharmafile.